ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease.

• 71% complete response (CR) rate in patients with BCG-unresponsive NMIBC CIS, with or without papillary disease
• Median duration of CR of 26.6 months, with responses extending beyond 53 months
• More than half of responding patients in the FDA-reviewed population maintained complete responses beyond 45 months
• 84% cystectomy-free survival at 36 months among responders
• 98.2% disease-specific survival at three years
• No Grade 4 or Grade 5 treatment-related adverse events reported

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.